Holen Sie sich die Stockscreener-App
55.65
1.48%
0.81
Handel nachbörslich:
55.66
0.010
+0.02%
Schlusskurs vom Vortag:
$54.84
Offen:
$54.95
24-Stunden-Volumen:
347.28K
Relative Volume:
0.68
Marktkapitalisierung:
$3.53B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-145.21M
KGV:
-24.20
EPS:
-2.3
Netto-Cashflow:
$-140.12M
1W Leistung:
+5.48%
1M Leistung:
+13.57%
6M Leistung:
+27.64%
1J Leistung:
+22.79%
1-Tages-Spanne:
$54.44
$55.96
1-Wochen-Bereich:
$51.08
$55.96
52-Wochen-Spanne:
$31.42
$58.26
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Firmenname
Moonlake Immunotherapeutics
Sektor
Branche
Telefon
41 41 510 8022
Adresse
DORFSTRASSE 29, ZUG
Vergleichen Sie MLTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
55.65 | 3.48B | 0 | -145.21M | -140.12M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-28 | Eingeleitet | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-17 | Hochstufung | Goldman | Neutral → Buy |
| 2024-11-05 | Fortgesetzt | Wedbush | Outperform |
| 2024-08-26 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-02 | Eingeleitet | Goldman | Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-08 | Eingeleitet | Citigroup | Buy |
| 2023-11-02 | Eingeleitet | Stifel | Buy |
| 2023-09-14 | Herabstufung | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | Eingeleitet | Needham | Buy |
| 2023-06-15 | Eingeleitet | Barclays | Equal Weight |
| 2023-05-01 | Eingeleitet | Guggenheim | Buy |
| 2023-03-22 | Eingeleitet | Wedbush | Outperform |
| 2023-03-09 | Eingeleitet | BTIG Research | Buy |
| 2023-02-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-02 | Eingeleitet | Bryan Garnier | Buy |
| 2022-11-11 | Eingeleitet | Jefferies | Buy |
| 2022-08-25 | Eingeleitet | SVB Leerink | Outperform |
| 2022-07-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-07 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Moonlake Immunotherapeutics Aktie (MLTX) Neueste Nachrichten
MoonLake Immunotherapeutics: Maintaining A Small Holding (NASDAQ:MLTX) - Seeking Alpha
MoonLake Immunotherapeutics: Robust Financials and Promising Phase 3 VELA Program Back Strong Buy Rating - AInvest
MoonLake Immunotherapeutics: Strong Buy Rating Amid Promising Phase 3 VELA Program and Robust Financial Position - TipRanks
Does Rising Loss at MoonLake Immunotherapeutics (MLTX) Signal Strategic Investment or Expense Control Challenges? - simplywall.st
Rising Losses Might Change the Case for Investing in MoonLake Immunotherapeutics (MLTX) - simplywall.st
Intraday Charts Show Spike in MoonLake Immunotherapeutics ActivitySwing Trade Entry With Volume Triggers Released - beatles.ru
Goldman Sachs Boosts MoonLake Pharmaceuticals Target Price to $82, Maintains "Buy" Rating - AInvest
Clear Street Analyst Reiterates Buy Rating for MoonLake Immunotherapeutics with $108 Price Target - AInvest
MoonLake Bets Big On Its Nanobody Drug As Key Trials Approach - Finimize
MoonLake Immunotherapeutics Reports Q2 2025 Financials - TipRanks
MoonLake Immunotherapeutics reports Q2 EPS (87c), consensus (76c) - TipRanks
Guggenheim reiterates Buy rating on Moonlake Immunotherapeutics stock By Investing.com - Investing.com South Africa
Guggenheim reiterates Buy rating on Moonlake Immunotherapeutics stock - Investing.com
MoonLake Immunotherapeutics: Buy Rating Driven by Promising SLK Phase 3 Data and Strong Financial Position - TipRanks
Clear Street Initiates MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Announces Target Price $108 - 富途牛牛
MoonLake Immunotherapeutics reports results for the quarter ended June 30Earnings Summary - TradingView
MoonLake Immunotherapeutics reports second quarter 2025 financial results and provides a business update - MarketScreener
MoonLake Immunotherapeutics Q2 Loss Widens - MarketScreener
MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update - Ariva
Earnings Flash (MLTX) MoonLake Immunotherapeutics Posts Q2 Net Loss $0.87 a Share, vs. FactSet Est of $0.68 Loss - MarketScreener
MoonLake Immunotherapeutics's Q2 net loss widens - MarketScreener
MoonLake Immunotherapeutics SEC 10-Q Report - TradingView
MoonLake Immunotherapeutics AG - Via Ritzau
How does MoonLake Immunotherapeutics compare to its industry peersDiscover stocks with explosive potential - Jammu Links News
Is it the right time to buy MoonLake Immunotherapeutics stockFree Consultation - Jammu Links News
What drives MoonLake Immunotherapeutics stock priceFree Stock Index Interpretation - Jammu Links News
How does MoonLake Immunotherapeutics generate profit in a changing economyDiscover top stock picks for aggressive growth - Jammu Links News
Is MoonLake Immunotherapeutics stock overvalued or undervaluedMaximize gains with professional stock picks - Jammu Links News
MoonLake Immunotherapeutics: Strategic Leadership Transition and Promising Clinical Progress Drive Buy Rating - TipRanks
Is MoonLake Immunotherapeutics a growth stock or a value stockTremendous wealth creation - Jammu Links News
What catalysts could drive MoonLake Immunotherapeutics stock higher in 2025Achieve remarkable returns with smart investing - Jammu Links News
What institutional investors are buying MoonLake Immunotherapeutics stockOutstanding capital returns - Jammu Links News
What are MoonLake Immunotherapeutics company’s key revenue driversIdentify breakout stocks before they peak - Jammu Links News
Published on: 2025-08-03 09:53:42 - Jammu Links News
What are analysts’ price targets for MoonLake Immunotherapeutics in the next 12 monthsPre Market Picks With High Returns - Jammu Links News
Phase 3 Trials Accelerate MoonLake Advances for Immunologic Disease Treatment - Insider Monkey
Pattern recognition hints at MoonLake Immunotherapeutics upsideReal-Time Analysis With Entry Targets In Progress - metal.it
MoonLake Immunotherapeutics Inches Toward Key Resistance — Will It BreakEntry Plan for Oversold Reversal Stocks Released - metal.it
Is Now a Good Time to Reenter MoonLake ImmunotherapeuticsSwing Trade Entry With Volume Triggers Released - metal.it
Published on: 2025-07-29 20:29:47 - beatles.ru
MoonLake Immunotherapeutics Company’s Quarterly Earnings Growth: What the Numbers SayWealth Building Stock Market Ideas Based on Momentum - metal.it
Promising Outlook for MoonLake Immunotherapeutics: Buy Rating Backed by Strong Position in Hidradenitis Suppurativa Treatment - TipRanks
What does MLTX's flat EPS in 2024 suggest for investors? - AInvest
Does MoonLake Immunotherapeutics stock perform well during market downturnsStock Market Data Feed For Consistent Profits - jammulinksnews.com
Published on: 2025-07-29 08:56:36 - metal.it
Finanzdaten der Moonlake Immunotherapeutics-Aktie (MLTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):